staff reporter
Articles Authored by staff reporter
Treos Bio, Roche Begin Combination Immunotherapy Study in Microsatellite-Stable Colorectal Cancer
The first patient has been dosed in a Phase II trial evaluating Treos' off-the-shelf immunotherapy PolyPEPI1018 and Roche's checkpoint inhibitor Tecentriq.Â
In Brief This Week: Lungevity, Grail, Mainz Biomed, Bayer, Scorpion, Caris Life Sciences
News items for the week of June 27, 2022.
Faeth Therapeutics Closes $47M Series A Round to Explore Precision Diet Cancer Therapy Benefits
In clinical trials, the firm will screen patients for their tumors' nutritional vulnerabilities, and dispense a complete diet to be used alongside drugs.
Blueprint Medicines Inks $1.25B Financing Deal in Exchange for Royalties of Ayvakit, Gavreto
Sixth Street is providing funds in exchange for future royalties of Ayvakit and the KIT D816V inhibitor BLU-263, while Royalty Pharma inked a similar deal for Gavreto.
Analysis of Tumor Mutation, Treatment Data Across Cancers Points to Predictive Biomarkers
With electronic health record and tumor panel sequence data from tens of thousands of cancer cases, researchers tallied relationships between gene alterations and patient outcomes.
Leukemia and Lymphoma Society Launches Master Protocol Trial in Childhood Leukemia
A genomic eligibility algorithm developed for the study will allow researchers to match patients to appropriate therapy trials.
Harbinger Health, Sarah Cannon Research Institute to Study Blood-Based Early Cancer Detection Test
Harbinger has teamed up with SCRI's CRO to launch a 10,000-participant study to validate its multi-cancer early detection platform.Â
Revolution Medicines Begins Phase I/Ib Trial in KRAS G12-Mutant Tumors
The trial will enroll around 140 patients with advanced solid tumors driven by KRAS variants, including G12A, G12D, G12R, G12S, or G12V.
Ideaya Biosciences Selects Lead Pol Theta Helicase Inhibitor for Development With GlaxoSmithKline
The companies are advancing the drug through IND-enabling studies, after which GSK will develop the agent in combination with its PARP Inhibitor Zejula.
European Commission Approves Gilead Sciences' Yescarta for Follicular Lymphoma Patients
The autologous CAR T-cell therapy is now available in Europe as a fourth-line option for relapsed or refractory follicular lymphoma patients.